Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230788 · ClinicalTrials.gov registry record · NA
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01230788: Clinical Trial NA study, sponsored by Emory University.
NCT01230788 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01230788, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute Lymphoblastic Leukemia (ALL). Rituximab was approved by the Food and Drug Administration in 1997. However, the use of rituximab with prednisone, etoposide, and ifosfamide in pediatric patients with relapsed or refractory ALL is considered experimental. This study is for patients who have ALL in second or greater relapse, or in first relapse and not responding to treatment. The goals of this study are: * To see if using rituximab with prednisone, etoposide, and ifosfamide is beneficial to leukemia treatment * To find out what side effects this combination of drugs can cause A total of 15 participants (30 years old or younger) will be enrolled, over a period of 2 years.
Primary Outcome
To estimate the 4 month EFS after therapy with rituximab and cytotoxic chemotherapy (prednisone/etoposide/ifosfamide) in patients with second relapse/refractory ALL.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-10 |
| Phase | NA |
Why NCT01230788 stopped before completion
NCT01230788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT01230788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01230788 about?
NCT01230788 is a clinical study titled "Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia". This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute Lymphoblastic Leukemia (ALL). Rituximab was approved by the Food and Drug Ad...
What is the current status of trial NCT01230788?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2010-09. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01230788?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT01230788?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01230788's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia